Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21905988 | 0.85 | SCN10A (0.59) | SCN10ASYK | |
| SCHEMBL21906140 | 0.84 | SCN10A (0.46) | SCN10ASYK | |
| SCHEMBL21906059 | 0.84 | SCN10A (0.62) | SCN10ASYK | |
| SCHEMBL21906035 | 0.83 | SCN10A (0.65) | SCN10A | |
| SCHEMBL21906172 | 0.80 | SCN10A (0.51) | SCN10A | |
| SCHEMBL29250043 | 0.80 | SCN10A (0.54) | SCN10ASYK | |
| SCHEMBL29250110 | 0.78 | SCN10A (0.46) | SCN10ASYK | |
| SCHEMBL21906073 | 0.77 | SCN10A (0.47) | SCN10A | |
| SCHEMBL30927448 | 0.77 | SCN10A (1.00) | SCN10A | |
| SCHEMBL21906050 | 0.73 | SCN10A (0.63) | SCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084064-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-03-13 | — | — | US | disclosed |
| US-12195445-B2 | 2-amino-N-heteroaryl-nicotinamides as Nav1.8 inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-01-14 | — | — | US | disclosed |
| CN-113272293-B | 2-Amino-N-heteroaryl-nicotinamide as NAV1.8 inhibitor | 默沙东有限责任公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20220289710-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2022-09-15 | — | — | US | disclosed |
| US-11377438-B2 | 2-amino-n-heteroaryl-nicotinamides as Nav1.8 inhibitors | MERCK SHARP & DOHME LLC (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210387966-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-12-16 | — | — | US | disclosed |
| EP-3873893-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-09-08 | — | — | EP | disclosed |
| CN-113272293-A | 2-amino-N-heteroaryl-nicotinamide as NAV1.8 inhibitors | 默沙东公司 | 2021-08-17 | — | — | CN | disclosed |
| US-20200140411-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12195445-B2 | 2-amino-N-heteroaryl-nicotinamides as Nav1.8 inhibitors | SCN8A, SCN2A, SCN1A | SCN10A 10/4885SYK 4227/4885 |
| US-20250084064-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN1A | SCN10A 10/4885SYK 4227/4885 |
| US-11377438-B2 | 2-amino-n-heteroaryl-nicotinamides as Nav1.8 inhibitors | SCN8A, SCN2A, SCN1A | SCN10A 10/4885SYK 4227/4885 |
| US-20220289710-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN1A | SCN10A 10/4885SYK 4227/4885 |
| US-20210387966-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN1A | SCN10A 10/4885SYK 4227/4885 |
| US-20200140411-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN1A | SCN10A 10/4885SYK 4227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.